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Available online 30 March 2018Lung cancer causes N1·6 million deaths annually, with early diagnosis being paramount to effective treatment.
Here we present a validated risk assessment model for lung cancer screening.
The prospective HUNT2 population study in Norway examined 65,237 people aged N20 years in 1995–97. After a
median of 15·2 years, 583 lung cancer cases had been diagnosed; 552 (94·7%) ever-smokers and 31 (5·3%)
never-smokers. We performedmultivariable analyses of 36 candidate risk predictors, usingmultiple imputation
ofmissing data and backwards feature selectionwith Cox regression. The resultingmodel was validated in an in-
dependent Norwegian prospective dataset of 45,341 ever-smokers, in which 675 lung cancers had been diag-
nosed after a median follow-up of 11·6 years.
Our final HUNT Lung Cancer Model included age, pack-years, smoking intensity, years since smoking cessation,
body mass index, daily cough, and hours of daily indoors exposure to smoke. External validation showed a
0·879 concordance index (95% CI [0·866–0·891]) with an area under the curve of 0·87 (95% CI [0·85–0·89])
within 6 years. Only 22% of ever-smokers would need screening to identify 81·85% of all lung cancers within
6 years.
Our model of seven variables is simple, accurate, and useful for screening selection.










Lung cancer (LC) is the leading cause of cancer mortality worldwide
(Torre et al., 2016), and early diagnosis is paramount for increasing sur-
vival. The National Lung Screening Trial (NLST) showed that low-dose
high-resolution computed axial tomography (CT) scanning of heavy
smokers (N30 pack-years, b15 years quit time) aged 55–74 at inclusion
time and at 6 years of follow-up reduced LC mortality by 20% (National
Lung Screening Trial Research Team, 2011). However, these simple
criteria are relatively ineffective. First, only an estimated 26·7% of
those who develop LC in a general population cohort fulfil the NLST in-
clusion criteria for CT screening (Pinsky and Berg, 2012). Second, out of
those included, false-positive or indolent LCs counted for 96·4% and 18%of Science and Technology,
icine, Prinsesse Kristinsgt. 1,
B.V. This is an open access article uof cases, respectively. In addition, the potential danger of unnecessary
invasive and potentially dangerous procedures, the psychological bur-
den of a false-positive finding, and risks associated with CT screening
are not negligible (Patz et al., 2014; Rampinelli et al., 2017). Specifically,
the risk for LC induced by the radiation from the CT screening is esti-
mated to be between 24 and 81/100000 cases after 10 years of CT
screening (Rampinelli et al., 2017).
The above arguments suggest a pressing need for improving the
NLST criteria for effective CT screening. In a European Union position
statement recently published in Lancet Oncology, risk stratification is
one of the keys to ensure the successful implementation of future
low-dose CT screening programmes in Europe (Oudkerk et al., 2017).
Several multivariable risk prediction models have been proposed to
improve the selection of people for LC screening (Ten Haaf et al., 2017;
Tammemagi et al., 2013). In addition to NLST's pack-years, quit-time,
and age, they consider other risk factors such as history of respiratory
diseases, exposure to occupational dust (asbestos, coal, silica), socioeco-
nomic status, body mass index (BMI), history of cancer, race, education,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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carcinoembryonic antigen, alpha-fetoprotein, and C-reactive protein
(Katki et al., 2016; Wu et al., 2016; Muller et al., 2017).
However, these models and corresponding studies also have a vari-
ety of potential issues such as age cutoffs, inclusion of mainly heavy
smokers, restricted and/or empirical inclusion of predictors and list-
wise exclusion of cases withmissing data, all of which call into question
the transferability of these models to clinical practice. Can we create a
model that can reliably predict LC across ages and smoking burdens?
To address this challenge, we developed a novel LC risk prediction
model for CT screening based on data from a large, prospective,
population-based study in Norway of 65,237 people aged 20–100 with
a median follow-up time of 15·2 years. Multivariable statistical
methods identified a minimal set of required factors to achieve optimal
prediction. The model has been successfully externally validated on a
larger independent cohort. Our study furthers the state-of-the-art by
developing a model trained on a population with a wider age group,
which includes light smokers, has a relatively long follow-up median
time, performsdata-driven selection of predictors, and does not exclude
cases with missing data (handled with multiple imputation).
2. Methods
2.1. Ethics
Participants included in HUNT2 and Cohort of Norway (CONOR) all
gave their written consent. The Norwegian Data Inspectorate and the
Regional Committees for Medical Research Ethics approved each indi-
vidual study.
2.2. Discovery Dataset: The HUNT2 Population
The Nord-Trøndelag Health Study (HUNT Study) is a collaboration
between HUNT Research Centre (Faculty of Medicine and Health Sci-
ences, Norwegian University of Science and Technology), Nord-
Trøndelag County Council, Central Norway Health Authority, and the
Norwegian Institute of Public Health.
From 1995 to 1997, HUNT2 invited 93,898 residents of Nord-
Trøndelag County in Norway, aged 20 years or more, to participate in
a health survey, and ≈70% (n = 65,237) responded (Krokstad et al.,
2013). The datawere collected through questionnaires on demographic
characteristics, medical history, and lifestyle (199 clinical variables/
questions selected from the HUNT2 Baseline Questionnaires 1 and 2
and Measurements NT2BLQ1, NT2BLQ2, and NT2BLM, respectively)
(HUNT, 2018). In 2012, our group was granted access to analyse the
HUNT2 data to identify LC cases and establish the HUNT2 discovery
dataset. We also linked the national 11-digit personal identification
number of each participant to the Norwegian Cancer and Death Cause
Registry. The diagnosis code of the International Classification of Dis-
eases 7162·1 was used. Individuals who died or migrated were
modelled as censored at the time they left the study; the latest follow-
up day for all participants was December 31, 2011. Those who devel-
oped other cancer types during the follow-up period (n = 6821), had
a LC diagnosis before their participation in HUNT2 (n = 16), or did
not answer any questionnaire in HUNT2 (n = 57) were excluded from
the current study, resulting in a subset of 58,343 eligible participants.
2.3. Variables
We identified 36 potential predictors out of the 199 including age,
sex, education, BMI, history of previous cancer, asthma, heart attack,
stroke, fractures, self-perceived health, various heart- and lung-related
symptoms, anxiety, muscle pain, detailed smoking history (including
indoor smoke exposure in hours and smoke exposure as a child),
asthmamedication, daily coffee use, and physical activity (Table 1, Sup-
plementary Table S1a). The selection criteria were based on known riskfactors for LC aswell as factors associatedwith other smoke-related dis-
eases. Ever-smokers were defined as thosewho responded positively to
the question, “Smoke daily now or ever?”; those who answered nega-
tive were defined as never-smokers.
2.4. Validation Dataset: The CONOR Population
The risk prediction model learned from the HUNT2 analysis was ap-
plied and externally validated on the ever-smokers in the CONOR data-
base. CONOR constitutes a national database of ten regional prospective
population-based studies of 173,236 individuals aged N19 that use the
same questionnaires as HUNT2 (Naess et al., 2008). Urban population
from the largest cities of Norway as well as rural population is repre-
sented. It also includes some participants born in non-European coun-
tries (HUBRO Study) (Sogaard et al., 2004) representing 1·4% of ever-
smokers and an unknown fraction of indigenous Sami people in studies
from northern Norway (Naess et al., 2008).
All participants with complete predictor data in CONOR were in-
cluded while all HUNT2 participants (n = 65,018) and never-smokers
(n = 21,649) were excluded. To simulate a true screening setting,
those with previous history or subsequently diagnosed with other can-
cers were not excluded.
2.5. Statistical Analysis
The original variableswere non-linearly transformedwhenever nec-
essary; specifically age, pack-years, quit-time, BMI, and hours of indoors
exposure to smoke. Missing values were imputed using multiple impu-
tation with predictive mean matching (R package mice) (van Buuren
and mice, 2011), resulting in 30 complete datasets. For each of them,
200 bootstrap datasets were generated, and backwards feature selec-
tion with the Akaike Information Criterion was performed on every
set using the R package rms (Harrell, 2001). Second-order interaction
terms were also tested for inclusion. The predictors that were returned
by the above procedure in the majority of datasets were selected in the
final model, and their regression coefficients were calculated according
to “Rubin's Rules” (Heymans et al., 2007). Internal validation was per-
formed with the bootstrap method; for all metrics, median and inter-
quartile range in the multiple imputed datasets are reported (robust
methods) (Marshall et al., 2009). Discriminative ability was measured
by the concordance index (C-index) metric. Calibration, i.e. agreement
between predicted and observed risks across subgroups of the popula-
tion, was evaluated by the predictiveness curve (Pepe et al., 2008). An
online risk calculator was created; the electronic version of the calcula-
tor is available at (http://mensxmachina.org/en/HUNT-NTNU-lung-
cancer-risk-calculator/). The results of the modelling process are also
presented by a nomogramwhere the relative importance of eachpredic-
tor is depicted andwhere the 5-, 10-, or 15-year estimates of the LC risk
could be calculated. The statistical methodology is presented in detail in
the Supplementary Appendix (Supplementary Figs. S1–4 andTable S1a–
b). The analysis conforms to the reporting standards of STARD/TRIPOD
(Moons et al., 2015; Bossuyt et al., 2015), and is depicted in Fig. 1.
2.6. Role of the Funding Source
The funding sources had no role in study conception, design, inter-
pretation of the data, writing of the report, or decision to submit the
paper for publication. The corresponding author confirms that he had
full access to all data in the study andfinal responsibility for the decision
to submit for publication.
3. Results
In the HUNT2 discovery cohort (n=58,343; 800,845 person-years),
57·5% of individuals were ever-smokers (n= 33,521; 469,404 person-
years), and 583 were diagnosed with LC during follow-up (median
Table 1
All 36 variables included in the backwards feature selection analysis. In univariate analysis, all variables except
those indicated in green had significant p values regarding the risk for LC diagnosis (p b 0.05, see Supplementary










































































































*The variables were selected from the HUNT2 Baseline Questionnaire 1, 2 and Measurements (NT2BLQ1,
NT2BLQ2, and NT2BLM respectively, see link https://www.ntnu.no/hunt/variabler and Supplementary
Table S1).
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dence of ~1%. Among LC cases, 552 (94·7%) were ever-smokers and
31 (5·3%) never-smokers; thus, incidence rates of LC per 10,000
person-years in never- and ever-smokers were 0·7 and 16·5, respec-
tively (Supplementary Table S1b).
3.1. Univariate Analysis
In univariate analysis, 30 of the 36 candidate variables indicated a
higher LC risk; among these were higher age, male gender, individuals
with lower education, lower BMI, individuals who had smoked more
pack-years, more cigarettes per day, and for longer durations. However,
several unexpected variables such as any incidence of heart attack, cur-
rent self-perceived health, muscle pain, insomnia, and daily intake of
cups of brewed coffee were also statistically significant (Table 1 and
Supplementary Table S1b).
3.2. Multivariable Risk Prediction Model (HUNT Lung Cancer Model)
Seven variables were selected by the backward selection procedure:
age, total smoking burden (pack-years), quit time (“If you previously
smoked, how long has it been since you stopped? Number of years”),
daily cough (“Do you cough daily during periods of the year?Yes or
No”), BMI, hours of indoor smoke exposure (“How long are you usually
in a smoky room each day? Number of hours”), and smoking intensity
(number of cigarettes per day) (Table 2, Supplementary Table S1a).
Hazard ratios for LC increasedwith age, pack-years, hours of daily expo-
sure to smoke, and cough daily during periods of the year. Hazard ratios
decreasedwith increasing BMI, quit time, and smoking intensity given afixed number of pack-years (e.g. smoking20pack-years by 40 cigarettes
per day for 10 years is less deleterious than 10 cigarettes per day for
40 years) (Table 2, Supplementary Table S4).
Using this model, the median C-index was 0·903 in the full cohort
(including never-smokers), whereas for ever-smokers in the same
group, the median C-index was 0·869 (Table 3, Tables S4 and S12). Cal-
ibrationwas satisfactory, with observed risks very close to the predicted
(Supplementary Figs. S3 and S4). However, it was not possible to de-
velop a model for the never-smokers with predictions better than ran-
dom guessing (data not shown), so the final model, the “HUNT Lung
Cancer Model”, included only ever-smokers. The model is presented as
a nomogram (Fig. 2a). An online risk calculator were also created; the
electronic version of the calculator is available at (http://
mensxmachina.org/en/HUNT-NTNU-lung-cancer-risk-calculator/).
The risk predictions were stratified into low-, medium-, and high-risk
groups using the 50% and 84% quantiles, as previously proposed (Royston
and Altman, 2013), and visualized by Kaplan–Meier curves, showing sta-
tistically significant differences between the groups by a log-rank test
(Fig. 2b, p = 0·0008). To estimate the absolute risk per individual, the
baseline risk of LC diagnosis (the survival function) was estimated ac-
cording to van Houwelingen (Supplementary Appendix). Sex did not
contribute significantly but was included for adjustment (Table 3; see
comment in Discussion). The detailed analysis of two separate gender-
specific models is described in the Supplementary Tables S7 and S8.
3.3. External Validation
In the external validation dataset (CONOR), amongparticipantswith
complete data (n = 67,036; 807,701 person-years), 67·7% were ever-
Fig. 1. Schematic representation of the analysis protocol. The analyses were performed on 36 selected predictorsmeasured on a cohort of 58,343 participants involved in the HUNT study.
Thirty distinct datasetswere created aftermissing data imputation, and selected variableswere transformed in a non-linear fashion. For eachof the 30 complete datasets, 200 bootstrapped
datasets were created, leading to a total number of 6000 training datasets. A backward feature selection (with Akaike Information Criterion as a stopping rule) was repeated on each
training dataset for selecting the most relevant risk factors for lung cancer. A final model was built over all variables chosen at least once during the feature selection procedure, and by
using Rubin's rule for estimating model coefficients from the 30 complete datasets. A total of 6000 separate bootstrapped validation datasets were created for assessing the
predictiveness of the model and for correcting for overfit. Both the fitting of the model and its evaluation were repeated for the whole cohort and for ever-smokers only.
39M. Markaki et al. / EBioMedicine 31 (2018) 36–46smokers (n = 45,341, 566,579 person-years) (Supplementary
Table S10). Median pack-years were 11·5. In this cohort, there were
709 LC events until 2011, 675 (95·5%) and 34 (4·5%) among ever-
and never-smokers, respectively, with a median follow-up-time of
11·6 years (Supplementary Tables S8–S9). The incidence rates of LC
per 10,000 person-years in never- and ever-smokers were 1·4 and
11·9, respectively.
Applying the HUNT Lung Cancer Model in the ever-smokers of the
validation cohort resulted in a C-index 0·879 (95% confidence interval
[CI] 0·866–0·891) (Table S11), close to the one estimated on the
HUNT data. Calibration was satisfactory (Supplementary Figs. S3 and
S4). The area under the curve (AUC) within 6 years was 0·87 (95% CI0·85–0·89). Setting the risk threshold to correspond to the 16%
quantile of the risk of events in HUNT (medium and high risk) equalled
a risk of 1·75% for developing LC within 16 years (N15 points in the no-
mogram) and a risk of 0·64% for developing LCwithin 6 years (Fig. 2b).
Based on this threshold, 221 of 270 LC events within 6 years (sensitivity
and specificity of 81.85% and 78.31%, respectively) and 527 of 675
events within ~20 years (sensitivity and specificity of 78.07% and
78.82%, respectively) were correctly predicted. More specifically, using
this threshold, one would need to examine 10,000 (22%) out of 45,387
ever-smokers to identify 81·85% of future LC events in a 6-year period
or 78% of future events in a 20-year period (median 11·6 years)
(Fig. 4d, Table 4).
Table 2
TheHUNT Lung CancerModel. Variables and questions to participants. Cox predictionmodel of lung cancer risk for 33,521HUNT2 participantswho had ever smoked⁎ and did not develop
any other type of cancer in a mean follow-up time of 13·2 years.
Variable Questions to participants Hazard ratio (95% CI) P value Beta
coefficient
Sex - 1·128 (0·941–1·352) 0·188 0·1205819
Agea Age at participation at screening 0·135 (0·098–0·186) b0·001 -2·0020557
Pack-years (log) Estimated number of pack-years 3·200 (2·451–4·176) b0·001 1·1630181
Smoking quit time, years (log) If you previously smoked, how long has it been since you stopped?
(Number of years)
0·786 (0·705–0·876) b0·001 -0·2407998
Body mass index (log) BMI 0·288 (0·153–0·539) b0·001 -1·2462656
Cough daily, yes vs no Do you cough daily during periods of the year? 1·501 (1·250–1·802) b0·001 0·4059355
Smoke exposure, hours (log) How long are you usually in a smoky room each day? (Number of hours) 1·181 (1·062–1·313) 0·002 0·1663201
Smoking intensity per 1 cigarette increase How many cigarettes do you or did you usually smoke daily? 0·971 (0·951–0·991) 0·004 -0·0295406
⁎ To calculate the 16-year lung cancer risk in one person with the use of categorical variables, multiply the beta coefficient of the variable by 1 if the factor is present and by 0 if it is
absent. For continuous variables other than age,multiply their value – or their log value if indicated – by the beta coefficient of the variable. For age, calculate its contribution by dividing by
100, exponentiated by the power−1, andmultiply by the beta coefficient of the variable. Calculate the sumof all previously calculated beta coefficient products; this sum is represented as
Xβ. To obtain the person's 16-year LC risk, calculate 1 − 0.06exp(Xβ). CI denotes confidence interval.
a Age had a non-linear association with LC and was transformed as (100/Age).
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The number of people in CONOR (validation population) fulfilling
NLST criteria was 2081; only 69 (25·6%) out of the 270 that developed
LC within 6 years were included in this group out of 2081 people. We
contrasted the performance of the HUNT Lung Cancer Model with the
NLST criteria, given the same number of individuals screened (n =
2081), by selecting the top 2081 highest-risk individuals in CONOR, as
assessed by the model (Table 5). The proposed model's criteria identi-
fied 103 vs 69 of NLST out of 270 cases showing an improved sensitivity
(38.14% vs 25.6%, P = 0.0216) and positive predictive value (4.95% vs
3.3%, P b 0.000001), with the same specificity (95.61% vs 95.5%, P =
0.7321) and similar negative predictive value (99.6% vs. 99.5%, P =
0.95374).Table 3
Key differences of the HUNT Lung Cancer Model over externally validated risk prediction mod




Marcus et al., 2015,
Raji et al., 2012
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Age limit 45–79 35+ 55–74
Median Pack-years 18·9 ≈30a ≈30
Never-smokers analysed Yes Yes No
Follow-up, years 8·7 mean 5 max 6 max
Feature selection Yes backward Yes, based on AUC and
tdNRI
No, pre-sp
Number of variables 14 (6 selected) 12 (4 selected) 11





Report on missing data Yes Yes No
MIc No No No
MI with feature selectionc No No No
Internal validation Yes No Yes
External validation Yes EPIC test set Yes
Discriminatory power (AUCd and/or C-indexe)
C-index AUC AUC
Total Population 0·849 NR NR
Ever-smokers NR AUC 5y) NR 0·803 (6 y




NR = not reported.
a Years of smoking more than N15 cigarettes per day.
b Bootstrap in each of 30 multiply imputed datasets.
c MI = multiple imputation.
d Area under the receiver operating curve.
e Concordance index.3.5. How to Apply the Model
A user-friendly LC risk calculator for 6 and 16 years was created
which has good prediction accuracy and seems well calibrated both in
HUNT and in CONOR (Supplementary Fig. S3). The nomogram provided
(Fig. 2a) can also be used to calculate LC risk. The nomogramvisually de-
picts the relationship between model variables and the LC risk: the
length of each variable axis is proportional to the contribution of this
variable to the total risk. One simply adds the contributions of all the
variables in the nomogram and the result reflects the personal risk of
this individual. In our calculations we set the risk threshold to corre-
spond to the 16% quantile of the risk of events in HUNT (medium and
high risk, Fig. 2b) equalling a risk of at least 1·75% for developing LC
within 16 years and at least 0.64% in 6 years (N15 points in theels developed in prospective population-based cohorts. AUC refers to prediction of 1-, 5-
l., 2017,







One county 70% of total adult
population (n=65 240)
One country, 11 health studies
ever-smokers (n=45 341)
= 20 = 20
10·3 11·5
Yes (n=24 725) Not applicable
13·2 mean 16 max
ecified Yes backward Not applicable










) 0·879 / 0·87 (6 y)
Fig. 2.A.Nomogram to calculate the calculate the personal 5-, 10-, and 15-year risk of lung cancer riskwith theuse of seven independent factors discovered bybackwards feature selection.
B. Low-,medium-, and high-risk groups for lung cancer according to the risk predictionmodel for ever-smokers. TheKaplan–Meier curves are plotted for risk groups defined from50% and
84% quantiles. Differences among the three curves were highly significant (p = 0·0008) according to the log-rank test. The number of event-free participants in every risk group at
different time points is shown above the x-axis.
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Lung Cancer Model nomogram or the online calculator, a 40-year old
person with 15 pack-years and full-score contribution with low BMI
(e.g. 22), low smoke intensity (e.g. 10 cigarettes per day), periodical ordaily cough, and many hours of indoor smoke exposure (e.g. 10 h,
total risk score N 15, LC risk = 1·77% at 16 years and 1.39% in 6 years)
would be assessed as a medium- or high-risk individual. A 56-year-old
with 15 pack-years, high BMI (e.g. 33), high smoke intensity (e.g. 40
Table 4
Performance of theHUNT Lung CancerModel versusNLST criteria for lung cancer (LC) diagnosiswithin 6 years in the validation cohort (CONOR) of ever-smokerswith complete data using
as threshold the 16% quantile of risk of events in HUNT corresponding to a LC risk at least 1·75% in ~16 years or 0·64% in 6 years or ~15 points in the nomogram. Of the 45,117 ever-
smokers, 1986 were picked by the NLST criteria. Sensitivity, specificity, PPV and NPV are calculated based on including all participants, 10,000, selected by the HUNT Lung Cancer Model.
Participants with LC (N) Participants without LC (N) Participants total (N) Predictive value
HUNT Lung Cancer Model criteriaa 270 45 117 45 387
Criteria positive 221 TP (2·21%) 9 779 FP (97·79%) 10 000 PPV 2·21%




Criteria positive 66 TP (0·66%) 9 934 FP (99·44%) 10 000a PPV 0·66%
Criteria negative 204 FN (0·57%) 35 183 TN (99·43) 35 387 NPV 99·43%
Sensitivity 24·44%
Specificity 77·98%
FN= false negative; FP = false positive; NPV = negative predictive value; PPV = positive predictive value; TN = true negative; TP = true positive.
a Total criteria positive selected by the HUNT Lung Cancer Model includes the 1986 picked by the NLST.
42 M. Markaki et al. / EBioMedicine 31 (2018) 36–46cigarettes per day), no periodical or daily cough, and no indoor smoke
exposure would be assigned a lower than cut-off risk and would not
be eligible for screening (risk score 12.5, LC risk = 1·35% at 16 years
and 0.61% at 6 years, Fig. 2a, b).
4. Discussion
Accurate risk predictionmodelling is key for selecting individuals for
LC screening by CT. Here we propose the HUNT Lung Cancer Model, a
simple yet highly predictive, externally validated model employing
seven clinical factors. Five of the seven were established previously
(age, pack-years, smoking intensity, BMI, and quit time) (Ten Haaf
et al., 2017), while two are novel (hours of indoor smoke exposure
and daily cough during periods of the year). The model is applicable to
ever-smokers of all ages.
The predictive performance of the HUNT Lung Cancer Model is rela-
tively high compared to other externally validated models in the litera-
ture and restricted to the task of predicting the 6-year LC incidence in
the validation cohort, the sensitivity and specificity was 81·9% and
78·3% respectively, and the AUC was 0·87 [0·85–0·89] (Tables 3 and
4). A direct comparison of performance is however only possible for
the NLST criteria, since each model was derived from a different popu-
lation. In a recent paper by Ten Haaf et al. (2017) reviewing predictive
models, the models including PLCOm2012, Bach, and the Two-Stage
Clonal Expansion model predicted 6-year LC incidence in the PLCO
chest radiography arm with an AUC estimated between 0·77 and 0·8.
In several recent validations studies of the PLCOm2012model in var-
ious populations of ever-smokers, there were also good AUC values
(AUC = 0·80–0·81) (Ten Haaf et al., 2017; Li et al., 2015; Weber
et al., 2017) and the EPIC study validation exhibited an estimatedTable 5
Accuracy of NLST versus the HUNT Lung CancerModel for lung cancer (LC) diagnosis within 6 y
plete data. As comparedwith NLST criteria, ourmodel's criteria identified 103 vs 69 out of 270 ca
value (4.95% vs 3.3%, P b 0.000001), with the same specificity (95.61% vs 95.5%, P = 0.7321) a
Criteriaa Participants with LC (N) Partic
NLST criteria 270 45,117
Criteria positive 69 TP (3·3%) 2012
Criteria negative 201 FN (0·5%) 43,105
Sensitivity 25·6%
Specificity 95·5%
HUNT Lung Cancer Model criteria
Criteria positive 103 TP (4·95%) 1978
Criteria negative 167 FN (0·4%) 43,139
Sensitivity 38·14%
Specificity 95·61
FN= false negative; FP = false positive; NPV = negative predictive value; PPV = positive pre
a NLST criteria for study entry included a history of cigarette smoking of at least 30 pack-yea
15 years.AUC of 0·843; however, participants in all these studies had an almost
double or triple median number of pack-years (Table 3) (Hoggart
et al., 2012). While different prediction models are not directly compa-
rable, due to various populations and study designs, the HUNT Lung
Cancer Model had high performance in terms of both AUC and C-
index, in addition to having the longest follow-up time and largest
age-span of all studies to date.
We adopted a data-driven approach for performing the analysis and
selecting the variables in the model. Methodologically, the analysis in-
cluded a novel pipeline consisting of non-linear transformation of the
continuous variables, testing for inclusion of second-order interaction
terms, using multiple imputation to address the uncertainty from
missing values, feature selection for determining the subset of impor-
tant factors, estimating coefficients according to Rubin's rules, and
bootstrapping for internal validation. The importance of non-linear
transformation was seen in the analysis of LC risk in the HUNT popula-
tion (Goodness-of-fit chi-squared statistic Supplementary Fig. S1 and
Supplementary Table S2). This non-linear effect is also corroborated in
the literature (Meiners et al., 2015). In contrast, the competing models,
including the NLST criteria, often focus on a single age group (Table 2)
and omit younger and older people. Importantly, among the LC cases
in CONOR, 21.35% were younger than 55 and 18.41% were above 74 at
baseline, indicating that the NLST age cut-offs by itself excludes almost
40% of LC in our cohort.
High smoking burden is a known strong risk factor for andwas pres-
ent in this study aswell. However, to our knowledge, no priormodel has
been fit or tested in cohorts of light smokers of all ages (Table 2). In the
HUNT2 and CONOR populations, median pack-years were 10·3 and
11·5, respectively, while 64% and 61% of ever-smokers who developed
LC had smoked b30 pack-years (Figs. 3a and 4a).ears, using the same number of screenings as NLST in the CONOR ever-smokers with com-
ses showing an improved sensitivity (38.14% vs 25.6%, P=0.0216) and positive predictive
nd similar negative predictive value (99.6% vs. 99.5%, P = 0.95374).
ipants without LC (N) Participants total (N) Predictive value
45,387
FP (96·7%) 2081 PPV 3·3%
TN (99·5%) 43,306 NPV 99·5%
FP (95·05%) 2081 PPV 4·95%
TN (99·6%) 43,306 NPV 99·6%
%
dictive value; TN = true negative; TP = true positive.
rs, age between 55 and 74 years and, for former smokers, cessation within the previous
43M. Markaki et al. / EBioMedicine 31 (2018) 36–46In linewith others, we found that smoking the same total number of
cigarettes over a long versus a short time span increases the risk of LC
and is a significant risk predictor in the model (Table 2, Fig. 2a)
(Vlaanderen et al., 2014). Interestingly, in a meta-analysis of 15 studies,
this correlationwas at best uncertain below20pack-years, however, we
found that this effect also persists in a light smoker population
(Vlaanderen et al., 2014).
The proposed model also found that smoking cessation is an impor-
tant factor inwhich the risk decreases according to the logarithmof ces-
sation time, in line with others (Fig. 2a) (Vlaanderen et al., 2014). In
HUNT2, 29% of those developing LC were former smokers and 27% had
quit b30 years previously (Fig. 3b). Imposing an empirical cutoff on
the quit time as in the NLST study is probably not the best strategy.
Meta-analysis has confirmed the inverse proportional role of BMI in
LC risk, but the biological basis for the protective effect of high BMI is not
well understood (Duan et al., 2015). Low BMI was also found to be a
negative predictor in the HUNT Lung Cancer Model. One explaining hy-
pothesis could be that the biological factors that produce weight loss in
smokers are a proxy for genetic susceptibility to LC.
Our analysis revealed two independent predictors that have not
been used in previous models: daily cough and hours of exposure to
smoke. Ever-smokers answering “yes” on the question “Do you cough
daily during periods of the year?” had a statistically significant higher
risk (Table 2). Daily cough is the only symptom of the ten included
that was selected by the analysis (Table 1). Chronic or periodic coughFig. 3. Smoking status among lung cancer cases inHUNT2. A. Pack-years distribution at enrolmen
30pack-years groups all had a similar size,with 70% of thosewho developed cancer having smo
27% of those who developed lung cancer had a smoking quit time of b30 years.is common and may be elicited by many non-cancer factors, including
exposure to cigarette smoke and environmental pollution and a is key
symptom in diseases such as chronic obstructive pulmonary disease
(COPD), asthma, eosinophilic bronchitis, rhinosinusitis, pulmonary fi-
brosis bronchiectasis and even gastro-oesophageal reflux disease
(Chung and Pavord, 2008; Kessler et al., 2011). In CONOR, 18·3% of
those who did not develop LC had this symptom versus 34·1% of
thosewhodeveloped LC (p b 10-e4, Table S10), indicatinghow common
this symptom is in the population. In current smokers it has been noted
as a predictor of LC (Islam and Schottenfeld, 1994). Daily cough in ever-
smokers could indicate early damage or frailty of the airways or be a
symptom of an early cancer and clearly warrants further study.
Answering a high number of hours to the question “How long are
you usually in a smoky room each day (hours)?”was a statistically sig-
nificant independent risk predictor in ever-smokers, indicating that
ever-smokers may also suffer damage from second-hand smoking of
their own or other smokers´ and that the total smoke exposure matters
(Table 2). Even in countries where indoor smoking has been banned, a
clinician should therefore remember to ask this question when
assessing LC risk for a current or a former smoker.
In line with several other studies we were unable to find signifi-
cant clinical predictors for LC risk in never-smokers (Weber et al.,
2017; Hoggart et al., 2012). Perhaps supplementing these studies
with molecular markers could lead to identifying predictors for this
subpopulation.t (not at diagnosis). Of importance, themajoritywere current smokers, and the 10, 20, and
kedb30 pack-years at baseline. B. Distribution of current and former smokers at enrolment;
Fig. 4.Characteristics of the lung cancer events in the validation population (CONOR)with 0–20years of follow-up. A. Overall distribution of smoke exposure in lung cancer cases in CONOR
(n = 709). B. Lung cancer event appearance in ever-smokers (n = 675) in the CONOR population after baseline (x-axis) according to age groups (colour code) and pack-years (y-axis)
showing that all age groups are represented in all pack-year groups. In the three vertical boxplot (B, C and D) median time to diagnosis is not significantly different between pack-year
groups (not shown). C. Lung cancer event appearance in the CONOR population (all dots) after baseline (x-axis) and pack-years (y-axis) according to NLST criteria (red dots; N30
pack-years, 55–74 years of age and b15 years quit time). Within 6 years, less than one third of the total cases would be included in the NLST screening (cases in red within the red
quadrant). D. HUNT Lung Cancer Model applied to the CONOR population after baseline registration. Lung cancer event appearance in the CONOR population after baseline (x-axis)
and pack-years (y-axis). Red dots are lung cancer cases predicted using the model according to medium- plus high-risk groups in HUNT (Fig. 2b) corresponding to the 16% quantile of
the risk of events in HUNT, equalled to a risk of 1·75% for developing LC within 16 years (N15 points in the nomogram). Based on this threshold, 221/270 LC events within 6 years (red
dots within the red square) and 527/675 events within ~20 years were correctly predicted. More specifically, using this threshold, one would need to examine 9998 out of 45,387
(22%) ever-smokers to identify 82% of future events in a 6-years period or 78% of future events in a 20-year period (median 11·6 years).
44 M. Markaki et al. / EBioMedicine 31 (2018) 36–46Sexwas not selected by the backwards feature selection process, but
its inclusion was enforced in the model as a commonly used factor in
risk models for cancer (Table 2, Supplementary Appendix). Neverthe-
less, its coefficient as well as its interaction with smoking variables
(Supplementary Tables S7–S8)was not found to be significant, in accor-
dance with an accumulated body of research showing that women ex-
posed to first- or second-hand cigarette smoke have the same risk as
men for developing LC (De Matteis et al., 2013).
A proxy for genetic susceptibility is included among the 36 variables
in the form of the question, “Do you have or have you ever had cancer?”
This variable was significant in the univariate but not the multivariate
analysis (Supplementary Table S1a and b). Family history of LC is a
known risk factor and a variable included in some prediction models
(Weber et al., 2017; Marcus et al., 2015). Family history of LC or cancer
in general, is a variable that is often hard to accurately obtain as some
people may not know details of their family history for various reasons.A model where all the variables can be obtained reliably and consis-
tently therefore has a clinical advantage.
Educational status is a known predictor for LC and may also be a
proxy indicator of social and economic status, including smokingbehav-
iour. Norway has had a public educational system and an egalitarian so-
cial democratic system since the 1950s that may explain why this
variable was not significant in this study. In addition, smoking behav-
iour is included in the model, which may explain the absence of the ef-
fect of the educational status when controlling for all other factors.
Regarding transferability to other populations, we do not know if
people from different social or ethnic background would need a differ-
ent model. In our validation population there were 1.4% non-
Europeans, there were populations from the capital and big cities as
well as a large population from rural areas, there were people born be-
foreWorldWar II and up to 1976 (Naess et al., 2008). Inmanyways the
population is quite heterogenous, which is a strength of the model.
45M. Markaki et al. / EBioMedicine 31 (2018) 36–46Some limitations of the study are the lack of someknownLC risk pre-
dictors, including history of COPD, occupational exposure to asbestos or
radon, and heredity. Regarding COPD, among the 36 chosen variables,
several proxies indicate a chronic lung condition, such as self-
perception of health, ever-asthma, ever-asthma medication, wheezing
last year, cough daily, coughwith phlegm, dyspnoea last year, andmed-
ication daily last year. These factors were significant only in the univar-
iate analysis, except daily cough, which was selected in the model
(Table 1, Supplementary Table S1b).
Radon exposure, pollution, and other environmental factors are
important, but the low LC rate of b6% never-smokers indicates a
minor contribution of non–smoke-related factors. Regarding asbestos
exposure, we do not know whether our model has the same accuracy
in predicting LC in heavily asbestos-exposed populations because as-
bestos inhalation highly potentiates the risk for LC, especially in
combination with cigarette smoking. Because of abolition of asbestos
in most industrialized countries in the 1980s, individuals heavily ex-
posed to asbestos are aminority, but this issue persists in some coun-
tries where asbestos is widely used (Roe and Stella, 2015). In other
areas of the world with high environmental or occupational carcino-
gen exposure, these factors would need to be addressed in future risk
models.
This study, based on data from large, prospective, population-based
studies in Norway with a long follow-up time, identified a new, highly
predictive risk model, the HUNT Lung Cancer Model. This is the first
risk prediction model developed and tested in a light-smoker popula-
tion of all ages. Our research proves the model's effectiveness in
selecting high-risk individuals for LC screening. A nomogram and an on-
line calculator facilitate the calculation of 5-, 10-, 15-year as well as the
6- and 16-year risk of LC diagnosis respectively. The innovation, com-
pared with previous models, is the establishment of seven significant
clinical predictors by feature selection, including newly identified pre-
dictors, such as daily cough and hours exposed to smoke. Furthermore,
the model's simplicity and its applicability to all ages and even light
smokers represents an important improvement to the NLST criteria,
for effective CT screening.
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